Stabilizing Cellular Barriers: Raising the Shields Against COVID-19.
Front Endocrinol (Lausanne)
; 11: 583006, 2020.
Artículo
en Inglés
| MEDLINE | ID: covidwho-883849
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its clinical manifestation (COVID-19; coronavirus disease 2019) have caused a worldwide health crisis. Disruption of epithelial and endothelial barriers is a key clinical turning point that differentiates patients who are likely to develop severe COVID-19 outcomes:
it marks a significant escalation in respiratory symptoms, loss of viral containment and a progression toward multi-organ dysfunction. These barrier mechanisms are independently compromised by known COVID-19 risk factors, including diabetes, obesity and aging thus, a synergism between these underlying conditions and SARS-CoV-2 mechanisms may explain why these risk factors correlate with more severe outcomes. This review examines the key cellular mechanisms that SARS-CoV-2 and its underlying risk factors utilize to disrupt barrier function. As an outlook, we propose that glucagon-like peptide 1 (GLP-1) may be a therapeutic intervention that can slow COVID-19 progression and improve clinical outcome following SARS-CoV-2 infection. GLP-1 signaling activates barrier-promoting processes that directly oppose the pro-inflammatory mechanisms commandeered by SARS-CoV-2 and its underlying risk factors.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Envejecimiento
/
Infecciones por Coronavirus
/
Diabetes Mellitus
/
Péptido 1 Similar al Glucagón
/
Betacoronavirus
/
Inflamación
/
Obesidad
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Front Endocrinol (Lausanne)
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Fendo.2020.583006
Similares
MEDLINE
...
LILACS
LIS